• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oncology: International Journal of Cancer Research and Treatment >Vaccination strategies in the treatment of lymphomas.
【24h】

Vaccination strategies in the treatment of lymphomas.

机译：淋巴瘤的疫苗接种策略。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Malignant lymphomas are clonal neoplasms of lymphoid origin. By definition, all cells of the malignant clone have undergone the same rearrangement of antigen receptor genes and express identical antigen receptor molecules (immunoglobulin for B cell lymphomas, T cell receptor for T cell lymphomas). The hypervariable stretches within the variable regions of these receptors are considered true tumor-specific antigens ('idiotypes'). In several animal models, protective humoral or cellular immunity can be induced against the malignant lymphoma by vaccination with the tumor-derived idiotype. Successful experimental immunization strategies in animals include idiotype protein vaccines combined with various adjuvants, genetically or immunologically modified lymphoma cells, idiotype-presenting dendritic cells, idiotype-encoding viral vectors, and DNA immunization. Firm evidence for the induction of lymphoma-specific immunity has also been obtained from human idiotype vaccination trials. Furthermore, some trials have provided strong but hitherto formally unproven evidence for clinical benefit of idiotype-vaccinated patients. Alternative vaccination approaches are based on immunologically modified tumor cells. Current research efforts concentrate on the identification of the most efficacious vaccination route, on definitive proof of clinical efficacy, and on the development of convenient methods to manufacture individual idiotype vaccines.
机译：恶性淋巴瘤是淋巴样起源的克隆性肿瘤。根据定义，恶性克隆的所有细胞都经历了相同的抗原受体基因重排，并表达相同的抗原受体分子（针对B细胞淋巴瘤的免疫球蛋白，针对T细胞淋巴瘤的T细胞受体）。这些受体的可变区内的高变延伸被认为是真正的肿瘤特异性抗原（“独特型”）。在几种动物模型中，可以通过接种源自肿瘤的独特型来诱导针对恶性淋巴瘤的保护性体液或细胞免疫。在动物中成功的实验性免疫策略包括结合各种佐剂的独特型蛋白疫苗，基因或免疫修饰的淋巴瘤细胞，独特型递呈的树突状细胞，独特型编码的病毒载体和DNA免疫。还从人类独特型疫苗接种试验中获得了诱导淋巴瘤特异性免疫的确凿证据。此外，一些试验为独特型疫苗接种患者的临床益处提供了有力但迄今尚未得到正式证实的证据。替代的疫苗接种方法基于经过免疫学修饰的肿瘤细胞。当前的研究工作集中在最有效的疫苗接种途径的鉴定，临床疗效的确切证据以及制造个体独特型疫苗的便利方法的开发上。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号